Amphera B.V.

Amphera B.V. is an advanced clinical-stage biotechnology company dedicated to developing innovative dendritic cell therapies in the fight against cancer. With a focus on immuno-oncology, Amphera B.V. is committed to pioneering new treatment options and improving patient outcomes. The primary address of Amphera B.V. is located in ’s-Hertogenbosch, nl.

Amphera B.V.’s leading therapy, MesoPher, utilizes autologous dendritic cells loaded with PheraLys, a lysate of tumor cell lines. This groundbreaking approach allows for the presentation of a wide array of tumor-associated antigens, making it particularly effective against pancreatic cancer and other cancers. Amphera B.V. aims to leverage its cutting-edge research and development to revolutionize cancer treatment.

Amphera B.V. continues to push the boundaries of biotechnology and cell therapy. With a strong foundation built on scientific excellence and a commitment to innovation, Amphera B.V. is poised to make a significant impact in the field of oncology. We invite the manager of Amphera B.V. to create a customized and exclusive company showcase and product listing on our platform to further enhance your visibility and commercial development.